论文部分内容阅读
急性心肌梗死及梗死后心力衰竭的主要病理生理基础是收缩性心肌组织的丢失,而干细胞治疗有望直接解决该核心机制。早期临床研究表明,冠状动脉内输注骨髓源性细胞治疗急性心肌梗死有一定疗效。但需要更大规模、优化设计的临床试验进一步评估该新兴治疗技术的安全性、可行性和疗效。为此,新近已有数个Ⅱ~Ⅲ期临床试验启动。更为重要的是,针对细胞治疗机制的质疑,具有心肌细胞分化潜能的新型细胞源已从临床前研究逐步走向临床研究,开启了心肌再生新时代的序幕。
The main pathophysiological basis of acute myocardial infarction and post-infarction heart failure is the loss of contractile myocardium, and stem cell therapy is expected to directly address this core mechanism. Early clinical studies have shown that intracoronary infusion of bone marrow-derived cells in the treatment of acute myocardial infarction have a certain effect. However, larger, well-designed clinical trials are needed to further assess the safety, feasibility and efficacy of this emerging therapeutic technology. To this end, several recent Ⅱ ~ Ⅲ clinical trials started. More importantly, in view of the challenge of cell therapy mechanism, a new type of cell source with the potential of cardiomyocyte differentiation has gradually progressed from preclinical research to clinical research, opening the curtain of a new era of myocardial regeneration.